By Dr. James W. Stark
The Food and Drug Administration has announced a delay in releasing their opinion on PLEGRIDY™ (peginterferon beta-1a) by approximately three months. Plegridy™ is essentially a form of Axonex™, which is administered every other week instead of weekly. The data from clinical trials show that this new formulation is equivalent to Axonex™ in terms of efficacy and safety.
Dr. Stephen Kanter, Supervisor of Rehabilitation Services at the IMSMP, spoke at Grand Rounds this week. He discussed his approach to MS patients with balance dysfunction. The discussion of this very disabling MS symptom was constructive to all the clinicians and will be helpful in improving the multidisciplinary care of our patients. To schedule a rehabilitation evaluation, contact the main line at (212) 265-8070.
For the latest information and news on our FDA-Approved Phase I Clinical Stem Cell Trial, please visit www.tischms.org
Please check out Dr. Williams appearance on the PIX11 Morning News! Here he discusses the symptoms of multiple sclerosis to raise MS awareness. http://video.pix11.com/Raising-awareness-and-recognizing-symptoms-of-MS...